# Ipamorelin Research: Pharmacokinetics, Mechanism, and the Evidence > Ipamorelin research, pharmacokinetics first: half-life ~2 h, clearance 0.078 L/h/kg, a single 40-minute GH pulse, the selectivity mechanism, and every key study cited. The half-life and clearance constants, the selectivity mechanism, the one human trial, and the comparisons to its sibling peptides — each cited to the primary source. ## Start here Most write-ups about Ipamorelin research start with mechanism. This one starts with the clock, because the timing data is the most solid thing in the file. In the single human study, ipamorelin left the bloodstream with a half-life of about 2 hours, and the growth-hormone burst it caused peaked around 40 minutes after the dose [2]. Mechanism comes next: ipamorelin fits the ghrelin receptor (the same docking site the hunger hormone uses) on pituitary cells and tells them to release a pulse of growth hormone [1]. Its claim to fame is being clean about it — in animals it raised growth hormone without raising the stress hormone cortisol [1]. Below, each finding gets its own section, with the species, the dose, and the route stated plainly. None of it is a human dosing instruction; all of it is what researchers measured in studies. ## The pharmacokinetics: half-life, clearance, and a single pulse The human pharmacokinetic-pharmacodynamic dataset is the anchor of this lens. Eight healthy male volunteers per dose level received five 15-minute intravenous infusions spanning 4.21 to 140.45 nmol/kg [2]. The kinetics were dose-proportional — linear across that range — with a terminal half-life of approximately 2 hours, a clearance of 0.078 L/h/kg, and a steady-state volume of distribution of 0.22 L/kg [2]. A volume of distribution of 0.22 L/kg is small: it tells you the peptide stays largely in the bloodstream rather than diffusing deep into tissue. Pharmacodynamically, the growth-hormone response was a single discrete pulse peaking at about 0.67 hours — 40 minutes — post-dose [2]. The animal pharmacokinetics extend the picture. In male rats, ipamorelin's plasma clearance was roughly five-fold lower than GHRP-6, with 60-80% of the dose recovered intact in bile and urine, indicating moderate metabolic stability, and an intranasal bioavailability of about 20% [7]. That five-fold clearance gap is mechanistically meaningful: the alpha-aminoisobutyric acid at position 1 and the D-amino acids in the sequence slow enzymatic breakdown. The combined message of the human and rat data is a peptide with a short but well-behaved, predictable elimination profile. ## The selectivity mechanism that named the molecule Ipamorelin (Aib-His-D-2-Nal-D-Phe-Lys-NH2) is a selective agonist of GHS-R1a — the growth hormone secretagogue receptor type 1a, which is the ghrelin receptor. Binding it on pituitary somatotrophs activates the Gq/phospholipase-C pathway, raises intracellular calcium, and releases growth hormone [1]. In its 1998 founding characterization, ipamorelin released growth hormone potently in primary rat pituitary cells, anaesthetised rats, and conscious swine, with a swine ED50 of 2.3 nmol/kg versus 3.9 nmol/kg for GHRP-6 [1]. The decisive result was the absence of off-target activity: it did not raise ACTH or cortisol above the level seen with GHRH even at doses more than 200-fold above the growth-hormone ED50 [1]. That is what made it the first highly GH-selective growth hormone secretagogue. A large-animal study in pigs separately evaluated the efficacy, potency, and GH-release specificity of ipamorelin and related secretagogues, confirming the selective profile that distinguishes it from earlier GHRPs [12]. The mechanism also reaches beyond the pituitary: ex vivo pancreatic tissue from normal and diabetic rats released insulin directly in response to ipamorelin (10^-12 to 10^-6 M) via calcium-channel and adrenergic/cholinergic pathways — a peripheral, GH-independent insulinotropic action [13]. ## The one human trial, in full The single published Phase 2 randomized controlled trial (NCT00672074) enrolled 114 adults undergoing open or laparoscopic bowel resection, giving 0.03 mg/kg of ipamorelin intravenously twice daily on postoperative days 1-7 or until discharge [3]. It missed its primary endpoint: median time to first tolerated meal was 25.3 hours with ipamorelin versus 32.6 hours with placebo (p=0.15) [3]. Treatment-emergent adverse events were actually lower in the ipamorelin arm (87.5%) than placebo (94.8%), so no ipamorelin-specific safety signal emerged in that perioperative window — but the drug did not work for the indication tested [3]. This is the defining human anchor: it is why no Phase 3 trial followed and why the compound was never approved [3]. ## Bone, body composition, and the freshest data Subcutaneous ipamorelin at 18, 90, and 450 microg/day (divided three times daily for 15 days) raised the longitudinal bone-growth rate of adult female Sprague-Dawley rats from 42 microm/day on vehicle to 44, 50, and 52 microm/day, with no change in total IGF-1, IGFBPs, or bone-turnover markers — a partly local, pulse-driven skeletal effect rather than a systemic IGF-1 effect [4]. The most recent published in-vivo study is a 2024 ferret experiment: intraperitoneal ipamorelin (1-3 mg/kg) inhibited cisplatin-induced body-weight loss by roughly 24% on the last day of the delayed phase, but had no anti-emetic effect on acute or delayed emesis, in contrast to centrally administered anamorelin [5]. In streptozotocin-diabetic mice, intravenous ipamorelin produced significantly greater growth-hormone hypersecretion (150 +/- 35 microg/L) than non-diabetic controls (62 +/- 11 microg/L), alongside hepatic GH-receptor resistance and suppressed IGF-1 — altered pharmacodynamics in a diabetic state [9]. A 2026 critical review of peptide use in sport flags ipamorelin as a widely promoted compound with serious safety concerns in uncontrolled use and an expanding detection framework [17]. ## What is ipamorelin peptide Ipamorelin peptide is a wholly synthetic pentapeptide — five amino acids, sequence Aib-His-D-2-Nal-D-Phe-Lys-NH2, molecular formula C38H49N9O5, molecular weight about 711.85 Da, CAS 170851-70-4 [1]. It was derived from GHRP-1 by removing the central Ala-Trp dipeptide, and the non-natural alpha-aminoisobutyric acid at position 1 plus the D-amino acids give it resistance to enzymatic breakdown [1]. Functionally it is a ghrelin mimetic: it activates GHS-R1a to release a growth-hormone pulse, but unlike natural ghrelin and earlier GHRPs it does so without significant cortisol or prolactin release [1]. It is a research peptide, not an approved drug [3]. The medicinal-chemistry value of the scaffold is documented: a peptidomimetic series derived from ipamorelin reached comparable in-vivo GH-releasing potency (ED50 ~2 nmol/kg IV in swine) while attaining roughly 10% oral bioavailability in dogs [11]. ## What is cjc-1295 ipamorelin CJC-1295 ipamorelin refers to the popular practice of pairing two peptides that act on different receptors. Ipamorelin is a ghrelin-receptor (GHS-R1a) agonist that releases growth hormone by one mechanism; CJC-1295 is a GHRH analog that acts on the separate GHRH receptor [1]. Because the two pathways are distinct and complementary, the rationale for combining them is mechanistic synergy — a GHRH analog and a GHRP together [1]. Critically, this is a single-agent rationale extrapolated to a combination: the CJC-1295 + ipamorelin pairing has never been studied in a controlled trial for any outcome. The evidence that exists is for each compound separately, not for the stack. ## Ipamorelin cjc-1295 The ipamorelin cjc-1295 combination is best understood through the half-life mismatch that drives its dosing logic in community protocols. Ipamorelin clears quickly — a terminal half-life of about 2 hours in humans, with its growth-hormone pulse peaking near 40 minutes [2]. CJC-1295 analogs are engineered for a far longer duration of action. Pairing a short-acting GHRP with a long-acting GHRH analog is the structural reason the two are combined. None of this is a human dosing instruction, and no combination pharmacokinetic study in humans exists; the only human ipamorelin pharmacokinetic data is the single-agent dataset [2]. ## Does cjc-1295 ipamorelin work For the combination specifically, there is no controlled-trial evidence either way — the CJC-1295 + ipamorelin pairing has not been tested as a combination for any outcome. For ipamorelin alone, the human efficacy record is one negative trial: the Phase 2 postoperative-ileus study missed its primary endpoint (25.3 h vs 32.6 h to first tolerated meal, p=0.15) [3]. What is reproducible is the pharmacology — ipamorelin reliably releases a growth-hormone pulse in animals and humans [1][2] — but a measurable hormone pulse is not the same as a proven clinical benefit. The honest answer is that the pharmacology works as described while clinical efficacy in humans has not been demonstrated. ## Ipamorelin vs sermorelin Ipamorelin and sermorelin release growth hormone by different mechanisms, which is the core of the comparison. Ipamorelin is a ghrelin-receptor (GHS-R1a) agonist — a growth-hormone-releasing peptide — whereas sermorelin is a GHRH analog that acts on the GHRH receptor [1]. They sit on opposite sides of the same axis: a GHRP versus a GHRH analog. Ipamorelin's signature is selectivity, releasing growth hormone without raising cortisol or prolactin [1], and its human pharmacokinetics are characterized (half-life ~2 h, clearance 0.078 L/h/kg) [2]. The mechanistic complementarity is exactly why GHRPs like ipamorelin are paired with GHRH analogs in community protocols, though such combinations remain untested in controlled trials. ## Ipamorelin vs tesamorelin Ipamorelin versus tesamorelin is another GHRP-versus-GHRH-analog comparison, with one sharp regulatory difference. Both influence the growth-hormone axis, but ipamorelin works through the ghrelin receptor (GHS-R1a) while tesamorelin is a stabilized GHRH analog acting on the GHRH receptor [1]. The decisive contrast is approval status: ipamorelin has never been approved for any indication and its only Phase 2 trial failed [3], whereas tesamorelin reached the market for a specific approved use. On selectivity, ipamorelin's defining trait is releasing growth hormone without raising cortisol or prolactin [1] — a property framed against earlier, less selective peptides rather than against GHRH analogs, which work upstream on a different receptor entirely. --- A telemetry-grade reading of the published ipamorelin record — the half-life, the clearance, and the single growth-hormone pulse logged and cited; no clinic behind the console and nothing here dosed, dispensed, or sold.